Sci-B-Vac® Late-Breaker Oral Presentation at EASL 2020

August 31, 2020 | Video

Data from the Phase 3 program evaluating Sci-B-Vac®, VBI's company’s tri-antigenic prophylactic hepatitis B (HBV) vaccine, was presented in a late-breaker oral presentation at The Digital International Liver CongressTM 2020 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL). During the presentation, Adam Finn, M.D., Ph.D., Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, discussed the successfully-met primary endpoint of CONSTANT – demonstration of consistency of immune response as measured by the geometric mean concentration (GMC) of hepatitis B antibodies (anti-HBs titers) across three consecutively-manufactured lots of vaccine.

View More Videos

  • VBI-1901: SNO Phase 2a Data & Clinical Update

    Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.

    Watch NowArrow
  • Preclinical Coronavirus Program Data Webcast

    VBI discusses preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.

    Watch NowArrow
  • VBI-1901: AACR Data and Clinical Update

  • VBI-1901: AACR 2020 Webcast

    David E. Anderson, Ph.D., discusses updated Part B data from the VBI’s ongoing Phase 1/2a study of VBI-1901.

    Watch NowArrow
  • First- and Second-Generation Hepatitis B Vaccines

  • VBI-1901 Therapeutic Cancer Vaccine Design

  • Preclinical Studies in Glioblastoma (“GBM”)

    In preclinical studies, VBI demonstrated that its vaccine candidate stimulated immune responses critical to efficacious anti-tumor immunity.

    Watch NowArrow
  • Next Steps in the Development of Sci-B-Vac™

    Sci-B-Vac™ is a licensed third-generation hepatitis B vaccine that has demonstrated safety and efficacy in over 300,000 patients. Sci-B-Vac™ is currently approved for use in Israel and in 14 other countries.

    Watch NowArrow
  • About Medulloblastoma (“MB”)

    Medulloblastoma is the most common malignant primary brain tumor in children.

    Watch NowArrow
  • About Glioblastoma (“GBM”)

    Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than sixteen months.

    Watch NowArrow
  • LPV™ Thermostability Platform

  • About Hepatitis B

    Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”) characterized by inflammation, injury, and even cell death.

    Watch NowArrow
  • Cytomegalovirus (“CMV”) Vaccine Candidate

  • Enveloped Virus-Like Particle (“eVLP”) Platform Technology

  • eVLP Platform Technology

    VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines.

    Watch NowArrow

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top